Sector: Health Care
Director information for QUIDELORTHO CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Ann D. Rhoads | Former Chief Financial Officer of Forty Seven, Inc.; Director | 60 | ["Former Chief Financial Officer of Forty Seven, Inc.","Former Executive Vice President and Chief Financial Officer of Zogenix, Inc.","Former Chief Financial Officer of Premier, Inc.","Former Vice President, Strategic Initiatives at Premier, Inc.","Investment professional with The Sprout Group","Audit committee financial expert","Extensive executive leadership and governance experience","Chair"] | ["Audit Committee"] | 2026 |
| Brian J. Blaser | President and Chief Executive Officer (“CEO”) of QuidelOrtho | 61 | ["President, CEO, and director since May 2024","Former Executive Vice President, Diagnostic Products at Abbott Laboratories","Experience in various strategic, operational and diagnostic roles at Abbott Laboratories","Leadership positions in operations, finance and engineering at Ortho Clinical Diagnostics, Eastman Kodak, and General Motors","Board member of Quanterix Corp., Meridian Bioscience Inc.","Senior advisor to McKinsey & Company","Member of the Board of Trustees of the University of Dayton","Chair of the AdvaMedDx Division Board of Directors","M.B.A. with a Finance concentration from the Rochester Institute of Technology","B.Sc. in Mechanical Engineering Technology from the University of Dayton"] | [] | 2026 |
| Edward L. Michael | Managing Partner and Co-founder of LionBird Ventures and former Executive Vice President, Diagnostics Products at Abbott Laboratories; Director | 69 | ["Managing Partner","Co-founder","Executive Vice President, Diagnostics Products at Abbott Laboratories","Managing Partner of LionBird Ventures","Executive Vice President at Abbott Laboratories","Substantial experience in the diagnostics industry","Chair"] | ["Compensation Committee","Science and Technology Committee","Audit"] | 2026 |
| Evelyn S. Dilsaver | Former President and Chief Executive Officer of Charles Schwab Investment Management; Director | 70 | ["Former President and Chief Executive Officer of Charles Schwab Investment Management","Leadership roles at The Charles Schwab Corporation for over 16 years","Director of Bailard Private Real Estate Fund","Advisory board member at Protiviti Inc.","B.A. in Accounting from California State University-Hayward","Participant in Stanford Graduate School of Business, Senior Executive Program","Extensive executive leadership experience in financial and healthcare industries","Experience serving on boards of various public companies"] | ["Audit Committee","Audit"] | 2026 |
| John R. Chiminski | Former Executive Chair, President and Chief Executive Officer of Catalent, Inc.; Director | 62 | ["Executive Chair of Catalent, Inc.","President and Chief Executive Officer of Catalent, Inc.","President and Chief Executive Officer of GE Medical Diagnostics","Vice President and General Manager of GE Healthcare’s Global Magnetic Resonance Business","Vice President and General Manager of Global Healthcare Services","20 years of experience at GE Healthcare"] | ["Audit Committee","Science and Technology Committee","Audit","Nominating and Governance"] | 2026 |
| Joseph D. Wilkins Jr. | Senior Advisor for THEO Transformation Advisory and former executive at Atlantic Health System, Quest Diagnostics and Danaher-Beckman Coulter; Director | 64 | ["Senior Advisor","former executive at Atlantic Health System","Quest Diagnostics","Danaher-Beckman Coulter","Senior advisor for THEO Transformation Advisory","Senior Vice President and Chief Transformation and Innovation Officer for Atlantic Health System","Led commercial operations teams at Quest Diagnostics","Various executive leadership roles at Danaher-Beckman Coulter for approximately 28 years","Board member at Providence Health and Services and TGR Foundation","B.A. and M.B.A. in healthcare finance from Argosy University","Board-certified in healthcare management","Fellow of the American College of Healthcare Executives","More than 40 years of experience in the diagnostics and healthcare industry"] | ["Compensation Committee","Nominating and Governance Committee","Audit","Compensation"] | 2026 |
| Kenneth F. Buechler, Ph.D. | Chair of the Board; Director | 72 | ["Co-founder","former President","Chief Scientific Officer of Biosite, Inc.","co-founded Biosite Inc.","held various roles at Biosite Inc.","senior research scientist at Hybritech Inc.","director of TriVirum, Inc.","chair of the board of directors of Sequenom Inc.","board of directors of Astute Medical Inc.","board of directors of Edico Genome Inc.","Ph.D. in Biochemistry","bachelor’s degree in Chemistry from Indiana University","extensive experience in diagnostics","executive leadership and governance experience","Chair"] | ["Nominating and Governance Committee","Science and Technology Committee (Chair)","Audit","Compensation"] | 2026 |
| Kenneth J. Widder, M.D. | Former Chief Executive Officer of Sydnexis, Inc.; Director | 73 | ["More than 30 years of experience working with biomedical companies","Former Executive Chair of OrphoMed Inc.","Founder, chair and Chief Executive Officer of Sydnexis, Inc.","General Partner with LVP Life Science Ventures","M.D. from Northwestern University","Trained in pathology at Duke University","Strong governance background","Chair"] | ["Nominating and Governance Committee (Chair)","Science and Technology Committee","Compensation"] | 2026 |
| Mary Lake Polan, M.D., Ph.D., M.P.H. | Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine; Director | 82 | ["Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine","Professor of Clinical Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine","Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine","B.A. degree from Connecticut College","Ph.D. in Molecular Biophysics and Biochemistry from Yale University School of Medicine","M.D. from Yale University School of Medicine","M.P.H. from the University of California, Berkeley","Extensive experience in women's health","Medical doctor and practicing gynecologist","Governance experience through service on boards of directors of other companies"] | ["Compensation Committee","Science and Technology Committee","Audit","Nominating and Governance"] | 2026 |
| Matthew W. Strobeck, Ph.D.(1) | Director | [] | ["Audit","Nominating and Governance"] | 2026 | |
| R. Scott Huennekens | Former Chairman, President and Chief Executive Officer of Verb Surgical, Inc.; Director | 61 | ["Interim President and Chief Executive Officer of Hyperfine, Inc.","President and Chief Executive Officer of Verb Surgical, Inc.","President and Chief Executive Officer and board member of Volcano Corporation","Chair of the board of directors of Envista Holdings Corporation","Director of NeuroPace Inc.","B.S. in Business Administration from the University of Southern California","M.B.A. from Harvard Business School","More than 20 years of executive leadership experience"] | ["Compensation Committee","Nominating and Corporate Governance Committee","Compensation","Nominating and Governance"] | 2026 |
